January 11, 2024
1 min watch
Save
VIDEO: Faricimab demonstrates reduction in pigment epithelial detachment
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
In this video, Esther M. Bowie, MD, discusses a post hoc analysis comparing faricimab and aflibercept for the reduction of pigment epithelial detachment in patients with wet age-related macular degeneration.
The data from the TENAYA and LUCERNE trials were presented at the American Academy of Ophthalmology meeting.
“Faricimab seems to be good at decreasing pigment epithelial detachment, especially the ones with serous PED,” Bowie, professor of ophthalmology at Penn State Health Milton S. Hershey Medical Center, said.
Reference:
- Lim JI, et al. How effective is anti-Ang-2 and anti-VEGF (faricimab) for neovascular AMD with pigment epithelial detachments? Presented at: American Academy of Ophthalmology meeting; Nov. 3-6, 2023; San Francisco.
Published by:
Sources/Disclosures
Collapse
Source:
Healio Interviews
Disclosures:
Bowie reports no relevant financial disclosures.
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.